Lataa...
TARGETED THERAPIES: Afatinib—new therapy option for EGFR-mutant lung cancer
On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R) EGFR substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of pati...
Tallennettuna:
| Julkaisussa: | Nat Rev Clin Oncol |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4665630/ https://ncbi.nlm.nih.gov/pubmed/23959269 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrclinonc.2013.154 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|